Mounjaro® and injection site reactions

How often reactions were reported

The US label compares Mounjaro® with placebo in two diabetes trials ^[1]. The European information adds three more placebo-controlled settings in which tirzepatide is authorised under the Mounjaro® name in the EU: weight management, obstructive sleep apnoea and heart failure with preserved ejection fraction ^[4]. Canada prints the diabetes pool by dose and a seven-trial pool without placebo ^[5].

What a typical reaction looks like

Across phase 3 trials, the most common signs were redness and itching. The worst reaction each person had was mild in 91% and moderate in 9%, and none was classed as serious ^[4]. Canada’s patient information gives bruising, pain, irritation, itching and rash as examples, and the European leaflet mentions itching or redness ^[4][5].

The European information places injection site reactions in its “common” band, up to 1 in 10 people, and pain at the injection site in the “uncommon” band, up to 1 in 100 ^[4]. Rates were higher in the weight-management, sleep apnoea and heart failure trials than in the diabetes trials, and the documents do not explain why ^[4]. In children aged 10 and older, reactions occurred in 6% of those who developed antibodies and in none of those who did not ^[1].

The antibody link

About half of adults in seven diabetes trials, 51% or 2,570 of 5,025, developed antibodies to tirzepatide during treatment; across European phase 3 studies the range was 45.1% to 65.1% ^[1][4]. Injection site reactions occurred in 4.6% of adults with these antibodies against 0.7% of those without, and allergic-type reactions showed a similar gap ^[1].

An analysis of the phase 3 trials by manufacturer scientists found that antibody status, antibody level and neutralising antibodies had no effect on tirzepatide’s blood levels or on how well it worked. Most hypersensitivity and injection site reactions in people with antibodies were mild to moderate, and most occurred or resolved regardless of antibody status ^[6]. The labels do not ask patients to arrange antibody tests; the figures describe what was measured in trials.

Where to inject, and why rotation matters

Three areas are named: the belly and the thigh, which you can reach yourself, and the back of the upper arm, which is for injections given by another person ^[1][3]. Tirzepatide reached similar blood levels from all three, so the choice is about comfort and rotation, not effectiveness ^[1]. The European leaflet adds that belly injections should be at least 5 cm from the navel ^[4].

Every label says to rotate. You can stay in the same area, but choose a different spot within it each week ^[3][4]. Canada’s vial instructions explain why: changing the site lowers the risk of lipodystrophy, which shows as pits or thickened skin, and of localised cutaneous amyloidosis, which shows as lumps ^[5]. The same instructions say not to inject where skin is pitted, thickened, lumpy, tender, bruised, scaly or hard, or into scars ^[5]. If you also use insulin, give it as a separate injection, never mixed, and not right next to the Mounjaro® site ^[1][2].

Technique points from the instructions

• Check the liquid first: it should be clear and colourless to slightly yellow, without particles or cloudiness ^[1][3].
• According to the US pen instructions, the pen can be used without first warming it up, and air bubbles or a drop of liquid on the needle tip are normal ^[3].
• Hold the pen against the skin until the second click; the dose is complete when the grey plunger is visible ^[3].
• A drop of blood or liquid on the skin afterwards is normal: press a cotton ball or gauze on the spot and do not rub it ^[3].
• With vials, use a new syringe and needle every time; MedlinePlus adds that the skin should be healthy at the chosen spot and cleaned with alcohol and allowed to dry before injecting ^[1][7].
• Never share a pen with another person, even with a new needle, because of the risk of passing on blood-borne infections ^[1][2].

Local reaction, infection or allergy?

MedlinePlus says some soreness at the injection site is expected, but redness, swelling, red streaks and fever are signs of infection that need a call to your provider ^[7]. A reaction confined to the spot is also different from a reaction affecting the whole body.

The US label warns that serious allergic reactions, including anaphylaxis and angioedema, have been reported with Mounjaro® ^[1]. Allergic-type reactions of any severity, such as hives or eczema, were reported by 3.2% on Mounjaro® against 1.7% on placebo in the diabetes trials; the European information gives 5.0% against 3.8% in weight-management trials and lists rash and dermatitis among examples ^[1][4]. MedlinePlus notes that anaphylaxis develops quickly, often within seconds or minutes, with symptoms such as hives, swelling of the face or tongue, wheezing and dizziness ^[8]. People with a previous serious allergy to tirzepatide or to any ingredient in the injection must not use it ^[1].

What to note for your prescriber

Useful details: which site and which day, how large the area was, whether it was red, itchy, painful or bruised, how many days it lasted, and whether it keeps appearing in the same area. Note any skin changes that do not fade between injections, such as dips, thickening or lumps, since those are what rotation aims to prevent ^[5]. The labels do not recommend any cream or tablet for injection site reactions, so ask your pharmacist or prescriber before using one.

Mounjaro® and KwikPen® are registered trademarks of Eli Lilly and Company. PepLabo is not affiliated with or endorsed by Eli Lilly and Company.

When to get help